Literature DB >> 15706429

Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment.

Riccardo Bartoletti1, Maurizio Dal Canto, Tommaso Cai, Mauro Piazzini, Fabrizio Travaglini, Andrea Gavazzi, Michelangelo Rizzo.   

Abstract

It has recently been shown that allelic abnormalities, detected by microsatellite analysis of the DNA extracted from urine sediment, can be successfully used for the detection of transitional cell carcinoma (TCC) of the bladder. The diagnostic accuracy of urinary cytology, urinary bladder cancer (UBC) marker, bladder tumor antigen (BTA) and microsatellite sequence alterations was compared in 42 patients who were recruited for the study. Of them, 30 had been diagnosed with TCC at cystoscopy plus biopsy (group A). Seven patients without any apparent lesions after trans-urethral resection (TUR) and 6 subsequent weeks of endovesical administration of bacillus Calmette-Guerin (BCG), had irritative symptoms. None of them had positive cytology or TCC bladder mucosa biopsies (group B). In the control group were 5 other subjects who were affected by benign prostatic hypertrophy and candidates for prostatectomy (group C). Urine and blood samples were obtained from all of the patients before surgery. Tumor tissue and normal mucosa samples were taken from groups A and C during surgery. Different urinary sediment analyses were performed by using both nuclear medicine and molecular tests. UBC and BTA-t analyses were carried out using monoclonal antibody tests while microsatellite analyses were performed using extracted DNA and electrophoresis of polymerase chain reaction (PCR) products on 13 different primers. Urinary cytological examinations were carried out using the Autocyte Preparation System(R). Urinary cytology confirmed the presence of TCC in 13.3% of patients. The BTA-t marker allowed the identification of 73.3% of cancers with 50% specificity; the UBC marker identified 63.3% of the cases with 41.6% specificity. Microsatellite analysis permitted the identification of 83.3% of the tumors with 100% specificity. DNA analysis demonstrated high sensitivity in patients affected by superficial (81.4%) or G1 (80%) tumors, even when cytological studies demonstrated little or no sensitivity. Microsatellite analysis is a highly-sensitive and specific marker for TCC diagnosis and its monitoring, especially in patients with low-stage and low-grade tumors. Other testing procedures failed to increase urinary cytological diagnostic significance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706429

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

Review 1.  Considerations on the use of diagnostic markers in management of patients with bladder cancer.

Authors:  Piyush K Agarwal; Peter C Black; Ashish M Kamat
Journal:  World J Urol       Date:  2007-12-19       Impact factor: 4.226

2.  Urine cytology and adjunct markers for detection and surveillance of bladder cancer.

Authors:  Peggy S Sullivan; Jessica B Chan; Mary R Levin; Jianyu Rao
Journal:  Am J Transl Res       Date:  2010-07-25       Impact factor: 4.060

3.  Loss of heterozygosis on chromosome 18q21-23 and muscle-invasive bladder cancer natural history.

Authors:  Tommaso Cai; Nicola Mondaini; Daniele Tiscione; Maurizio Dal Canto; Raffaella Santi; Riccardo Bartoletti; Gabriella Nesi
Journal:  Oncol Lett       Date:  2015-08-17       Impact factor: 2.967

Review 4.  Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions.

Authors:  Chulso Moon; Maxie Gordon; David Moon; Thomas Reynolds
Journal:  Int J Mol Sci       Date:  2021-11-28       Impact factor: 5.923

5.  Selection of microsatellite markers for bladder cancer diagnosis without the need for corresponding blood.

Authors:  Angela A G van Tilborg; Lucie C Kompier; Irene Lurkin; Ricardo Poort; Samira El Bouazzaoui; Kirstin van der Keur; Tahlita Zuiverloon; Lars Dyrskjot; Torben F Orntoft; Monique J Roobol; Ellen C Zwarthoff
Journal:  PLoS One       Date:  2012-08-22       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.